Figure 1From: The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors Disposition of patients in the study. *One patient was nonrandomly assigned to Arm A and received treatment with motesanib 125 mg QD. †Total shown does not reflect 2 additional patients who discontinued motesanib for other reasons but later were granted a waiver to continue in a rollover study.Back to article page